Craig-Hallum resumed coverage of Joint Corp. with a Hold rating and $9.50 price target. The firm says it has no prior template on how Joint clinics perform during slowing economies, which “remains an uncertainty that will hamper the stock multiple.” While the company may continue to open franchised clinics, the total growth rate is set to slow into single digits and investors are likely to remain cautious until visibility improves on future EBITDA margins, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JYNT:
- Joint Corp. price target lowered to $30 from $50 at Lake Street
- Joint Corp. price target lowered to $13 from $16 at Roth MKM
- Joint Corp. lowers Q2 revenue view to $115M-$118M from $123M and $128M
- The Joint Corp. Reports Preliminary Second Quarter 2023 Financial Results
- Joint Corp. reports Q2 EPS 1c, consensus 1c
